These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27555120)

  • 21. Antiphospholipid antibodies and the kidney.
    Asherson RA; Kant KS
    J Rheumatol; 1993 Aug; 20(8):1268-72. PubMed ID: 8230004
    [No Abstract]   [Full Text] [Related]  

  • 22. Antiphospholipid Syndrome and Renal Allograft Thrombosis.
    Morales JM; Serrano M; Martinez-Flores JA; Perez D; Serrano A
    Transplantation; 2019 Mar; 103(3):481-486. PubMed ID: 30376553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and treatment of APS renal involvement.
    Tektonidou MG
    Lupus; 2014 Oct; 23(12):1276-8. PubMed ID: 25228725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal manifestations of the antiphospholipid syndrome.
    Piette JC; Cacoub P; Wechsler B
    Semin Arthritis Rheum; 1994 Jun; 23(6):357-66. PubMed ID: 7939722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal infarction in a severely hypertensive patient with lupus erythematosus and antiphospholipid antibodies.
    Hernández D; Dominguez ML; Diaz F; Fernandez ML; Lorenzo V; Rodriguez A; Torres A
    Nephron; 1996; 72(2):298-301. PubMed ID: 8684543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The intrarenal vascular lesions associated with primary antiphospholipid syndrome.
    Nochy D; Daugas E; Droz D; Beaufils H; Grünfeld JP; Piette JC; Bariety J; Hill G
    J Am Soc Nephrol; 1999 Mar; 10(3):507-18. PubMed ID: 10073601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report.
    Dufour I; Venot Q; Aydin S; Demoulin N; Canaud G; Morelle J
    Am J Kidney Dis; 2020 Aug; 76(2):288-291. PubMed ID: 31810732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in our understanding of the antiphospholipid syndrome.
    De Groot PG; Meijers JC; Urbanus RT
    Int J Lab Hematol; 2012 Jun; 34(3):223-31. PubMed ID: 22394675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Antiphospholipid syndrome in nephrology. Kidney damage and practical aspects of the management].
    Dekeyser M; Zuily S; Champigneulle J; Eschwège V; Frimat L; Perret-Guillaume C; Wahl D
    Nephrol Ther; 2014 Feb; 10(1):1-9. PubMed ID: 24113198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report.
    Zhou XJ; Chen M; Wang SX; Zhou FD; Zhao MH
    Lupus; 2017 Jun; 26(7):777-782. PubMed ID: 27913748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent trends in the management of antiphospholipid syndrome (Hughes syndrome).
    Espinosa G; Cervera R
    Drugs Today (Barc); 2010 Jan; 46(1):39-47. PubMed ID: 20200695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal involvement in antiphospholipid syndrome.
    Pons-Estel GJ; Cervera R
    Curr Rheumatol Rep; 2014 Feb; 16(2):397. PubMed ID: 24357443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiphospholipid antibodies: lessons from the bench.
    Koike T; Bohgaki M; Amengual O; Atsumi T
    J Autoimmun; 2007; 28(2-3):129-33. PubMed ID: 17383159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.
    Tektonidou MG
    Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):131-40. PubMed ID: 19048414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies.
    Cervera R; Espinosa G
    Expert Opin Ther Targets; 2010 Dec; 14(12):1279-82. PubMed ID: 21058919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characterization of antiphospholipid syndrome by detection of IgG antibodies against β2 -glycoprotein i domain 1 and domain 4/5: ratio of anti-domain 1 to anti-domain 4/5 as a useful new biomarker for antiphospholipid syndrome.
    Andreoli L; Chighizola CB; Nalli C; Gerosa M; Borghi MO; Pregnolato F; Grossi C; Zanola A; Allegri F; Norman GL; Mahler M; Meroni PL; Tincani A
    Arthritis Rheumatol; 2015 May; 67(8):2196-204. PubMed ID: 25939498
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients.
    Sinico RA; Cavazzana I; Nuzzo M; Vianelli M; Napodano P; Scaini P; Tincani A
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1211-7. PubMed ID: 20430943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management.
    Scheen M; Adedjouma A; Esteve E; Buob D; Abisror N; Planche V; Fain O; Boffa JJ; De Seigneux S; Mekinian A; Haidar F
    Autoimmun Rev; 2022 May; 21(5):103072. PubMed ID: 35217200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.